ASCO: Bicara Therapeutics Demonstrates Deep and Durable Responses in Head & Neck Cancer

 

• Bicara Therapeutics' Phase 1/1b trial for ficerafusp alfa combined with pembrolizumab shows promising results in HPV-negative head and neck cancer.
• Key findings include a 54% objective response rate, 21% complete response rate, and a median duration of response of 21.7 months.
• Ficerafusp alfa exhibits a manageable safety profile, supporting its continued development in the FORTIFI-HN01 Phase 2/3 trial.

https://www.gurufocus.com/news/2900209/bicara-therapeutics-demonstrates-deep-and-durable-responses-with-ficerafusp-alfa-plus-pembrolizumab-in-1l-hpvnegative-rm-hnscc-at-asco-2025-bcax-stock-news